TESTOSTERONE + DROSTANOLONE BLEND

DUAL COMPOUND ANDROGEN FORMULATION

400 mg mL

INTRAMUSCULAR INJECTION

PRODUCT OVERVIEW

Specification	Details
Generic Name	Testosterone and Drostanolone Blend
Drug Class	Androgen / Anabolic-Androgenic Steroid
Active Ingredients	Testosterone Enanthate, Drostanolone Enanthate
Administration Route	Intramuscular Injection
Dosage Form	Oil-Based Injectable Solution
Chemical Class	Esterified Androgen and DHT-Derived Steroid
Primary Target	Androgen Receptor
Clinical Status	Testosterone Replacement / Androgen Therapy

INTRODUCTION

Testosterone + Drostanolone Blend is a concentrated injectable formulation containing testosterone enanthate and drostanolone enanthate. Both components are esterified anabolic-androgenic steroids formulated for gradual release from an intramuscular oil depot.

After administration, the esters are hydrolyzed to active testosterone and drostanolone. Both hormones activate androgen receptors, while their metabolism, androgenic profile, estrogenic conversion, and tissue-specific effects differ. The combined formulation therefore represents a dual-compound androgen preparation rather than a conventional testosterone-only blend.

HISTORY

Testosterone and drostanolone were characterized during the development of steroid-hormone therapeutics in the twentieth century. Esterification was used to increase lipid solubility and extend release after intramuscular administration.

Testosterone enanthate became an established long-acting testosterone preparation. Drostanolone was developed as a synthetic dihydrotestosterone derivative and was historically investigated in the treatment of advanced breast cancer. Drostanolone enanthate is not an established FDA-approved human medicine.

Testosterone + Drostanolone Blend combines these two esterified hormones in a non-standardized formulation. This specific 400 mg/mL combination does not represent an independently FDA-approved fixed-dose product, and its regulatory status depends on the manufacturer and jurisdiction.

CHEMICAL STRUCTURE

Testosterone enanthate is the enanthate ester of testosterone, while drostanolone enanthate is the enanthate ester of drostanolone. Drostanolone is a 2α-methyl derivative of dihydrotestosterone with a modified androgenic steroid nucleus.

The 2α-methyl substitution distinguishes drostanolone from dihydrotestosterone and influences its anabolic-androgenic profile. Esterification at the 17β-hydroxyl position increases lipid solubility and supports prolonged release from an intramuscular depot.

- Two esterified anabolic-androgenic components
- Testosterone and dihydrotestosterone-derived steroid nuclei
- Oil-soluble injectable formulation
- Hydrolysis to testosterone and drostanolone after release
- Sustained depot-release characteristics

CHEMICAL PROFILE

Parameter	Information
Primary Components	Testosterone Enanthate and Drostanolone Enanthate
Hormone Classification	Anabolic-Androgenic Steroids
Administration	Intramuscular Injection
Dosage Form	Oil-Based Injectable Solution
Molecular Type	Esterified Steroid Hormones
Primary Receptor Target	Androgen Receptor
Testosterone Enanthate	200 mg/mL
Drostanolone Enanthate	200 mg/mL
Total Concentration	400 mg/mL

PHARMACOLOGY

Testosterone + Drostanolone Blend acts as a source of two exogenous anabolic-androgenic hormones. Following intramuscular administration, testosterone enanthate and drostanolone enanthate are gradually released from the oil depot and hydrolyzed by esterases.

Testosterone and drostanolone enter target cells and bind to intracellular androgen receptors. The resulting receptor complexes influence gene transcription involved in reproductive physiology, skeletal muscle, bone metabolism, erythropoiesis, and other androgen-responsive processes.

Testosterone Enanthate + Drostanolone Enanthate → Depot Release and Ester Hydrolysis → Active Hormones → Androgen-Receptor Activation → Androgen-Responsive Gene Expression

Testosterone may be converted to dihydrotestosterone and estradiol. Drostanolone is a dihydrotestosterone-derived steroid that does not aromatize to estradiol and has a distinct androgenic and metabolic profile.

MECHANISM OF ACTION

The primary mechanism involves:

- Gradual release of both esterified hormones from the intramuscular depot
- Enzymatic hydrolysis to active testosterone and drostanolone
- Binding of both hormones to intracellular androgen receptors
- Regulation of androgen-responsive gene transcription

- Tissue-specific metabolism of testosterone and drostanolone
- Potential conversion to estrogenic and reduced metabolites
- Modulation of protein, nitrogen, bone, and reproductive physiology

Although both components activate androgen receptors, their metabolism and relative anabolic, androgenic, and aromatization profiles are not identical.

PHARMACODYNAMICS

- Androgen-receptor signaling
- Protein metabolism
- Nitrogen retention
- Erythropoiesis
- Bone metabolism
- Sexual and reproductive physiology
- Secondary male sexual characteristics
- Endocrine feedback regulation

SKELETAL MUSCLE SYSTEM

Testosterone interacts with androgen receptors in skeletal muscle and may influence:

- Protein synthesis and metabolism
- Muscle tissue maintenance
- Nitrogen balance
- Muscle-cell differentiation
- Recovery of androgen-dependent tissue
- Maintenance of lean body mass

Androgen-receptor signaling contributes to the regulation of normal skeletal-muscle structure, function, and metabolism.

SKELETAL SYSTEM

Androgen and estrogen signaling contribute to skeletal physiology and may influence:

- Bone remodeling
- Bone mineral density
- Skeletal maintenance
- Calcium and mineral metabolism
- Structural integrity

A portion of testosterone is converted to estradiol, which also has an important role in maintaining normal bone physiology.

CONNECTIVE TISSUE

Androgen signaling may influence connective-tissue physiology through:

- Structural protein metabolism
- Tissue maintenance

- Tissue remodeling
- Collagen metabolism
- Interaction with musculoskeletal adaptation

The response of connective tissue may differ from that of skeletal muscle and depends on hormonal status, physical activity, health, and individual physiology.

REPRODUCTIVE SYSTEM

Testosterone interacts with androgen-sensitive tissues and may influence:

- Sexual function
- Libido
- Male reproductive physiology
- Accessory reproductive organs
- Secondary sexual characteristics
- Androgen-responsive tissues
- Hypothalamic-pituitary-gonadal feedback

Exogenous testosterone can suppress luteinizing hormone and follicle-stimulating hormone, potentially reducing intratesticular testosterone production and spermatogenesis.

PHARMACOKINETICS

Following intramuscular injection, testosterone enanthate and drostanolone enanthate remain temporarily within an oil-based depot. Their ester structures support gradual absorption and prolonged release into the circulation.

Testosterone enanthate provides sustained testosterone exposure, while drostanolone enanthate generally exhibits a prolonged depot-release profile associated with its longer decanoate ester. Release characteristics depend on formulation, injection site, oil vehicle, and individual physiology.

After hydrolysis, testosterone and drostanolone circulate extensively bound to plasma proteins and undergo hepatic and peripheral metabolism. Their metabolites are eliminated primarily through urine, with smaller amounts eliminated through other pathways.

The complete pharmacokinetic profile of this specific 400 mg/mL fixed-ratio blend has not been established through standardized clinical studies.

PHYSIOLOGICAL EFFECTS

Testosterone and drostanolone both activate androgen receptors and may influence protein metabolism, nitrogen balance, skeletal muscle, bone tissue, erythropoiesis, reproductive physiology, and androgen-responsive tissues.

Testosterone provides the physiological actions associated with the principal endogenous male androgen. Drostanolone is a synthetic dihydrotestosterone derivative with androgen-receptor activity, no direct aromatization, and a distinct anabolic-androgenic profile. These characteristics do not establish an approved indication for the blend.

Exposure above physiological requirements can increase the likelihood of endocrine suppression, fertility impairment, erythrocytosis, lipid changes, fluid retention, acne, cardiovascular complications, and other androgen-related adverse effects.

CLINICAL APPLICATIONS

Approved testosterone preparations are used primarily for replacement therapy in appropriately evaluated patients with confirmed androgen deficiency. Drostanolone has historical antineoplastic use but does not have an established current FDA-approved therapeutic indication.

The clinical use of testosterone requires assessment of diagnosis, comorbidities, fertility goals, hematological status, cardiovascular health, and formulation-specific risks. The inclusion of drostanolone does not create an approved clinical indication and adds further androgen-related considerations.

This specific testosterone enanthate and drostanolone enanthate 400 mg/mL blend is not a universally standardized or independently FDA-approved fixed-dose medicine. Its status must be distinguished from approved single-ingredient testosterone products.

SAFETY CONSIDERATIONS

Testosterone exposure requires consideration of cardiovascular, hematological, endocrine, reproductive, metabolic, prostate, hepatic, and psychological health.

Important safety considerations include:

- Cardiovascular health
- Blood pressure
- Hematocrit and hemoglobin
- Lipid profile
- Liver function
- Endocrine function
- Reproductive function and fertility
- Prostate health
- Sleep apnea risk
- Fluid retention
- Injection-site reactions

The overall safety profile depends on the formulation, concentration, duration of exposure, individual response, and patient characteristics. Medical evaluation and regular monitoring are important whenever testosterone therapy is clinically indicated.

POTENTIAL ADVERSE EFFECTS

Potential adverse effects associated with testosterone and other anabolic-androgenic steroids may involve endocrine, cardiovascular, hematological, dermatological, reproductive, hepatic, metabolic, and psychological systems.

Endocrine Effects

- Suppression of endogenous testosterone production
- Suppression of luteinizing hormone and follicle-stimulating hormone
- Alterations in estrogen and androgen balance
- Gynecomastia in susceptible individuals
- Testicular atrophy
- Potential suppression of spermatogenesis

Cardiovascular Effects

- Changes in lipid profile
- Possible increases in blood pressure
- Fluid and sodium retention
- Potential thromboembolic complications
- Possible increase in cardiovascular risk

Hematological Effects

- Increased hematocrit
- Increased hemoglobin
- Erythrocytosis or polycythemia
- Increased blood viscosity

Dermatological Effects

- Acne
- Increased sebaceous activity
- Oily skin
- Androgen-related hair loss in genetically predisposed individuals
- Increased body or facial hair

Reproductive Effects

- Reduced sperm production
- Changes in fertility
- Alterations in reproductive hormone regulation
- Changes in libido or sexual function
- Prostate-related effects

Hepatic and Metabolic Effects

- Changes in lipid parameters
- Alterations in glucose metabolism
- Changes in liver-function parameters
- Fluid and electrolyte imbalance
- Changes in body composition

Administration Related Effects

- Injection-site pain
- Swelling or irritation
- Inflammatory reactions
- Hypersensitivity to active ingredients or excipients
- Infection when administration is not performed under appropriate sterile conditions

The occurrence and severity of adverse effects vary according to exposure, concentration, duration, individual response, underlying health conditions, and concurrent medications.

CONTRAINDICATIONS

Condition	Reason
Known or Suspected Prostate Carcinoma	Androgen-sensitive disease may be stimulated
Known or Suspected Male Breast Carcinoma	Potential androgen-sensitive malignancy
Pregnancy	Testosterone may cause fetal harm
Breastfeeding	Insufficient safety and potential hormonal exposure
Known Hypersensitivity	Risk of allergic reaction to active ingredients or excipients
Unexplained Elevated Hematocrit	Increased risk of erythrocytosis-related complications
Severe Uncontrolled Cardiovascular Disease	Potential fluid, blood-pressure, and cardiovascular effects
Severe Hepatic or Renal Disease	Potential fluid retention and impaired clinical tolerance

DRUG INTERACTIONS

Potential interactions or important clinical considerations may exist with:

- Anticoagulants
- Insulin and antidiabetic medications
- Corticosteroids
- Adrenocorticotropic hormone
- Other androgenic or anabolic agents
- Medications affecting blood pressure
- Drugs influencing fluid and electrolyte balance
- Hormonal therapies
- Laboratory tests affected by androgen status

Testosterone may alter anticoagulant response, glucose-control requirements, fluid retention, and selected laboratory measurements. The clinical significance depends on the specific medication, health condition, formulation, exposure, and individual response.

LABORATORY MONITORING

Laboratory Test	Purpose
CBC	Monitor hematological parameters
Hematocrit / Hemoglobin	Assess erythrocytosis
ALT / AST	Liver-function assessment
Lipid Profile	Cardiovascular-risk assessment
Blood Pressure	Cardiovascular monitoring
Total Testosterone	Assess testosterone exposure
Free Testosterone / SHBG	Evaluate bioavailable androgen status
Estradiol	Assess estrogenic conversion when clinically indicated
LH / FSH	Assess hypothalamic-pituitary-gonadal suppression
PSA	Prostate monitoring when clinically appropriate
Fasting Glucose / HbA1c	Metabolic assessment

STORAGE AND STABILITY

- Store according to official product labeling.
- Protect from excessive heat and direct sunlight.
- Do not freeze.
- Maintain original packaging integrity.
- Keep away from children.
- Inspect the solution and packaging before use.
- Do not use if the container is damaged or the solution shows unexpected contamination.
- Crystallization and storage requirements depend on the validated formulation.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality-verification features.

- Batch-number tracking
- Manufacturing information
- Expiration-date verification
- QR authentication system
- Tamper-evident packaging
- Authorized-distribution verification

NEXON emphasizes transparency, traceability, and product-quality control.

FREQUENTLY ASKED QUESTIONS

What is Testosterone + Drostanolone Blend?

Testosterone + Drostanolone Blend is a concentrated oil-based injectable formulation containing testosterone enanthate and drostanolone enanthate.

Which active ingredients are included?

The selected formulation contains equal concentrations of testosterone enanthate and drostanolone enanthate.

What does 400 mg/mL represent?

It represents the combined labeled concentration of the two esterified steroid ingredients: 400 mg per mL.

Is Testosterone + Drostanolone Blend a peptide?

No. It is an esterified androgen formulation and belongs to the anabolic-androgenic steroid class.

Is Testosterone + Drostanolone Blend a SARM?

No. Testosterone is a steroid hormone that activates androgen receptors and is not classified as a selective androgen-receptor modulator.

Is Testosterone + Drostanolone Blend oral or injectable?

It is presented as an oil-based solution intended for intramuscular administration.

Why are testosterone and drostanolone combined?

The combination creates a dual-compound androgen profile in which testosterone and drostanolone contribute different metabolic and pharmacodynamic characteristics.

Do testosterone and drostanolone have different biological actions?

Yes. Both activate androgen receptors, but drostanolone differs from testosterone in chemical structure, metabolism, aromatization, androgenic profile, and other tissue-specific properties.

Can Testosterone + Drostanolone Blend suppress natural testosterone production?

Yes. Exogenous testosterone can suppress hypothalamic-pituitary-gonadal signaling, including luteinizing hormone, follicle-stimulating hormone, endogenous testosterone production, and spermatogenesis.

Is this specific blend an FDA-approved formulation?

No independent FDA approval has been established for this specific testosterone and drostanolone, 400 mg/mL combination. Drostanolone enanthate does not have an established FDA-approved human therapeutic indication.

NEXON QUALITY COMMITMENT

NEXON is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality-control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

- Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution.
- Nieschlag E, Behre HM. Andrology: Male Reproductive Health and Dysfunction.
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
- Kicman AT. Pharmacology of Anabolic Steroids.
- Handelsman DJ. Androgen Physiology, Pharmacology, Use and Misuse.
- Basaria S. Androgen Abuse in Athletes: Detection and Consequences.
- Shahidi NT. A Review of the Chemistry, Biological Action, and Clinical Applications of Anabolic-Androgenic Steroids.
- Mooradian AD, Morley JE, Korenman SG. Biological Actions of Androgens.
- Snyder PJ. Clinical Use of Androgens.
- Wilson JD. Androgen Physiology and Pharmacology.
- Swerdloff RS, Wang C. Androgen Deficiency and Testosterone Replacement.
- U.S. Food and Drug Administration. Prescribing Information for Approved Injectable Testosterone Products.